Novotech Strengthens Presence in Japan with Opening of Tokyo Office
24.8.2026 01:01:00 CEST | Business Wire | Press Release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/
Takeshi Mori, Novotech Country Head, Japan
The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, FDA-aligned protocol development, US-based scientific expertise, and international partnering opportunities.
Japan is one of the world’s largest and most advanced pharmaceutical markets, supported by a sophisticated research base and a rapidly evolving biotech sector. As more Japanese biopharma companies look to expand beyond domestic development and bring novel therapies to global markets, Novotech’s expanded presence in Tokyo strengthens its ability to support cross-border clinical trials and connect sponsors across Asia-Pacific, the United States, and Europe.
Novotech’s global operating model is particularly well aligned to the needs of emerging and growth-stage biopharma companies, providing flexible, high-quality clinical development support without the complexity of managing multiple regional providers. The company brings deep experience across therapeutic areas including oncology, rare diseases, central nervous system disorders, infectious diseases, immunology, and advanced therapies, supported by strong regulatory, scientific, and operational expertise across major clinical trial markets.
Takeshi Mori, Country Head, Japan, commented:
“The opening of our Tokyo office is an important milestone for Novotech. Japan is a critical market for global clinical development, and this investment reflects our long-term commitment to building strong local capabilities while delivering high-quality services to our clients.”
The office is located at:
27F Shinjuku i-Land Tower, 6-5-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan 163-1327
The opening of the Tokyo office builds on Novotech’s established presence in Japan and reflects its broader strategy to strengthen its global footprint and position itself as a leading CRO partner for biotech companies worldwide.
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 7,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide.
Recipient of numerous industry accolades, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
For more information or to speak to an expert team member visit www.Novotech-CRO.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260823592174/en/
Contacts
Media Contact
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press Release
Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to further extend its category leadership among legal-age consumers of nicotine products. Like the flagship FDA-authorized ZYN pouches, ZYNULTRA, with its higher moisture content, is fre
58% of Consumers Say They Don't Care Whether a Product is a National Brand or Private Label. They Just Buy What They Need21.8.2026 12:00:00 CEST | Press Release
As fast-moving consumer goods (FMCG) prices rose 26% globally between 2021 and 2025, consumers have become more deliberate about where they save and where they spend. NielsenIQ (NYSE: NIQ) has released new findings showing that private label is no longer viewed simply as a lower-cost substitute, but as a credible competitor across value, mainstream, and premium segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819950224/en/ Private label is no longer just a value play. The findings, published in NIQ’s latest report, A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, created in collaboration with World Data Lab, show how consumer polarization is redefining value and reshaping competition on the shelf. The report also draws on insights from NIQ's 2025reportFinding Harmony on the Shelfwhich documented changing perceptions of private label products. Key findings from these reports include: 58
Cinemo, Dolby, and SmashLabs Bring In-Car Immersive Gaming Experiences to the Next Level21.8.2026 11:18:00 CEST | Press Release
Cinemo, a global leader and one-stop-shop provider for fully integrated, innovative multi-device in-car infotainment solutions, today announced a collaboration with Dolby Laboratories and SmashLabs to bring immersive, music-led gaming into the vehicle cabin creating highly engaging entertainment experiences across a broad range of in-car moments, whether on the move, parked, or while charging. Three technologies come together as SmashLabs’ games are integrated with Cinemo’s standardized In-Car Game APIs, translating in-game events into real-time vehicle responses. Dolby Atmos® adds immersive audio that moves sound around the cabin, allowing passengers to perceive direction and distance as an integral part of the gameplay. The result is a responsive in-car experience that brings gameplay to life through synchronized sound, lighting, haptics and climate control - tailored to each vehicle model. “The car is becoming a space where technology creates moments people genuinely remember, see,
Tanium Reappoints Co-Founder Orion Hindawi as CEO to Drive Next Chapter of Growth20.8.2026 21:10:00 CEST | Press Release
Tanium, a leader in Autonomous IT, today announced that Co-Founder and Executive Chairman Orion Hindawi has been appointed Chief Executive Officer, effective immediately. Dan Streetman is stepping down as CEO and as a member of the Board after leading Tanium for the last three years, during which time Tanium scaled its go-to-market operations and secured strong industry analyst recognition for innovation within the Tanium platform. Streetman will continue to advise Tanium as part of the transition and co-founder David Hindawi will return to the role of Chairman of the Board. With this foundation in place, this transition positions Tanium to deepen its Autonomous IT capabilities and further expand AI offerings across its portfolio and strengthen customer and partner engagement. The Hindawis co-founded Tanium in 2007 to build the central nervous system of enterprise security, giving organizations unified visibility and control over their endpoints. During his prior tenure as CEO from 201
PCI Energy Solutions to Join Mitsubishi Electric, Reinforcing Long-Term Commitment to Customers, Employees, and the Energy Industry20.8.2026 19:46:00 CEST | Press Release
PCI Energy Solutions ("PCI"), a leading U.S.-based provider of enterprise software for energy management and optimization, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi Electric Corporation. The agreement was executed on August 20, 2026 (Japan Standard Time). The Transaction represents a strong endorsement of PCI's business, technology, employees, customer relationships and position in the energy industry. Mitsubishi Electric intends to retain PCI's core management team following completion of the Transaction, enabling PCI to preserve leadership continuity, industry expertise and its customer-focused operating model while benefiting from Mitsubishi Electric's global scale, complementary capabilities and long-term investment capacity. The agreement has been signed, but the Transaction has not yet closed. PCI and Mitsubishi Electric will continue to operate as separate companies until closing, which is subject to applicable regulatory approv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom